Incannex Healthcare supports the White House Executive Order signed by President Donald J. Trump on April 18, directing the Food and Drug Administration to expedite the review of psychedelic drugs. The company believes its PSX-001 development program aligns with the goals outlined in the order, which may accelerate access to treatment for those suffering from anxiety disorders and other serious mental illnesses.
PSX-001 Clinical Data
PSX-001 is an oral, fixed-dose synthetic psilocybin formulation in development for Generalized Anxiety Disorder (GAD), a condition affecting an estimated 280 million people globally and approximately 6.8 million in the United States. In Incannex’s completed Phase 2 clinical trial, PSX-001 demonstrated statistically significant and clinically meaningful improvements across all primary and secondary endpoints. Results showed a 12.8-point reduction in HAM-A anxiety scores versus 3.6 points for placebo, with a 44% rate of clinically meaningful response (≥50% anxiety reduction)—four times the placebo rate. The program achieved a 27% remission rate (HAM-A ≤7)—five times the placebo rate, sustained through 11 weeks. There were no serious adverse events and a single discontinuation across 73 patients.
Executive Order Impact
The Executive Order’s direction to the FDA to prioritize review of psychedelic compounds with Breakthrough Therapy designations, create Right to Try pathways for investigational psychedelics, and initiate DEA rescheduling upon successful Phase 3 completion will meaningfully reduce regulatory and commercial risk for the psilocybin class broadly. Incannex CEO Joel Latham said the order “represents a meaningful step toward ensuring that novel, evidence-based therapies like ours can reach them without unnecessary delay.” The company is well-funded with over $70 million in cash and no debt, with an active U.S. IND and Phase 2 data described as among the strongest in the oral psilocybin space.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1111016705/Incannex-Healthcare-PSX-001-Program-Aligns-With-White-House-Executive-Order-Accelerating-Access-To-Psychedelic-Treatments-For-Serious-Mental-Illness